Matchpoint Therapeutics
Wei Li is a seasoned professional in the field of biology with extensive experience in leadership roles across various biotechnology and pharmaceutical companies. Currently serving as Vice President of Biology at Matchpoint Therapeutics since May 2021, Wei previously held consultancy positions and senior director roles at Quench Bio. Wei’s career began at Eisai US as a Research Biologist, followed by significant contributions at Millennium Pharmaceuticals, Pfizer, and Atlas Venture NewCo, culminating in roles as Associate Research Fellow and Senior Principal Scientist. This trajectory highlights a solid foundation in research and development, underscored by a commitment to advancing biological sciences.
This person is not in any offices
Matchpoint Therapeutics
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology.